Encompass Health Co. (NYSE:EHC) Shares Sold by Prudent Man Advisors LLC

Prudent Man Advisors LLC reduced its holdings in Encompass Health Co. (NYSE:EHC) by 1.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,617 shares of the company’s stock after selling 128 shares during the period. Prudent Man Advisors LLC’s holdings in Encompass Health were worth $833,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of EHC. UMB Bank n.a. boosted its stake in Encompass Health by 387.7% during the third quarter. UMB Bank n.a. now owns 317 shares of the company’s stock worth $31,000 after buying an additional 252 shares during the last quarter. V Square Quantitative Management LLC boosted its holdings in Encompass Health by 53.0% in the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock valued at $39,000 after purchasing an additional 140 shares during the last quarter. Oakworth Capital Inc. purchased a new stake in shares of Encompass Health in the 2nd quarter valued at approximately $40,000. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Encompass Health by 58.9% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company’s stock worth $46,000 after buying an additional 198 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Encompass Health in the second quarter valued at approximately $58,000. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Price Performance

Shares of NYSE EHC opened at $98.85 on Monday. The stock’s 50-day simple moving average is $96.38 and its 200-day simple moving average is $90.35. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.04 and a current ratio of 1.04. The firm has a market capitalization of $9.96 billion, a PE ratio of 23.88, a price-to-earnings-growth ratio of 1.31 and a beta of 0.88. Encompass Health Co. has a fifty-two week low of $63.59 and a fifty-two week high of $104.55.

Encompass Health (NYSE:EHC) last posted its earnings results on Monday, October 28th. The company reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.09. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same period last year, the firm posted $0.86 EPS. The company’s revenue was up 11.9% on a year-over-year basis. As a group, equities research analysts forecast that Encompass Health Co. will post 4.29 EPS for the current fiscal year.

Encompass Health announced that its board has approved a stock repurchase plan on Wednesday, July 24th that allows the company to repurchase $500.00 million in shares. This repurchase authorization allows the company to reacquire up to 5.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.

Encompass Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Thursday, January 2nd will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date is Thursday, January 2nd. Encompass Health’s dividend payout ratio is currently 16.43%.

Analysts Set New Price Targets

A number of analysts recently issued reports on EHC shares. KeyCorp raised their price objective on Encompass Health from $115.00 to $117.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 29th. Stephens restated an “overweight” rating and issued a $105.00 price objective on shares of Encompass Health in a report on Tuesday, August 6th. Truist Financial reissued a “buy” rating and issued a $116.00 target price (up previously from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. UBS Group increased their target price on Encompass Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Finally, Barclays boosted their price target on shares of Encompass Health from $109.00 to $116.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 29th. Nine investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $107.11.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.